Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 4, 2016, Pages 807-817

  Ouellet, Daniele ^a,b   Kassir, Nastya ^c   Chiu, Joannellyn ^a,d   Mouksassi, Mohamad Samer ^c   Leonowens, Cathrine ^a,e   Cox, Donna ^f,g   DeMarini, Douglas J ^f   Gardner, Olivia ^a,b   Crist, Wendy ^b,f   Patel, Kiran ^b,f  

^a GLAXOSMITHKLINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Pharsight A Certara Company   (Canada)

^d Inncelerex   (United States)

^e GENENTECH INC   (United States)

^f Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^g TEVA PHARMACEUTICALS   (Israel)

Author keywords

Exposure response; MEK inhibitor; Melanoma; NONMEM; Pharmacokinetics

Indexed keywords

B RAF KINASE; LACTATE DEHYDROGENASE; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; CLINICAL EFFECTIVENESS; COMPARTMENT MODEL; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MILD HEPATIC IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PERIPHERAL VOLUME OF DISTRIBUTION; PHARMACOGENETICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES;

EID: 84960121395     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-2993-y     Document Type: Article

References (19)

1. Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534
2. Gillmartin AG, Bleam MR, Groy A et al (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17:989-1000
3. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:948-954
4. Infante J, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VGR, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA III, Messersmith WA (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773-781
5. Leonowens C, Pendry C, Bauman J, Young GC, Ho M, Henriquez F, Fang L, Morrison RA, Orford K, Ouellet D (2014) Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol 78(3):524-532
6. Cox DS, Papdopoulos K, Fang L, Bauman J, LoRusso P, Tolcher A, Patnaik A, Pnedry C, Orford K, Ouellet D (2013) Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib a first-in-class MEK inhibitor, in patients with cancer. J Clin Pharmacol. doi: 10.1002/jcph.115
7. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD (2013) Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clinical Oncol 31(4):482-489
8. Flaherty KT, Robert C, Hersey P, Nathan P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114
9. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VJR, Lebowitz PF, Le NT, Burris HA III, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-789
10. Ho MYK, Morris MJ, Pirhalla JL, Bauman JW, Pendry CB, Orford KW, Morrison RA, Cox DS (2014) Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica. doi: 10.3109/00498254.2013.831143
11. Beal S, Sheiner LB, Boeckmann A (2011) NONMEM user's guides. Icon Development Solutions Ellicott City, Maryland
12. Harrell FE (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York
13. Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28(3):231-252
14. Wahlby U, Bouw MR, Jonsson EN, Karlsson MO (2002) Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 29(3):251-269
15. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
16. Bergstrand M, Hooker AC, Allini JE, Karlsson MO (2011) Prediction corrected visual predictive checks for diagnosing nonlinear mixed effects models. AAPS J 13(2):143-151
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 45:228-247
18. Flaherty KT, Hennig M, Lee S, Ascierto PA et al (2014) Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. doi: 10.1016/S1470-2045(14)70007-5
19. Chiu J, Ouellet D. Exposure-response analysis of the effect of trametinib, a MEK inhibitor, on tumor size in patients with V600 BRAF mutation positive melanoma. In: American conference on pharmacometrics (ACoP) meeting 2013; abstract W-017, Fort Lauderdale